Fluid infusion methods for glaucoma treatment

• US 8,617,094 B2
• Filed: 01/12/2006
• Issued: 12/31/2013
• Est. Priority Date: 03/07/2002
• Status: Active Grant

• Current Assignee: Glaukos Corporation
• Original Assignee: Glaukos Corporation
• Inventors: Smedley, Gregory, Haffner, David, Tu, Hosheng
• Primary Examiner(s): Zalukaeva, Tatyana
• Assistant Examiner(s): MARCETICH, ADAM M
• Application Number:
  US11/332,746
• Publication Number:
  US 20060116626A1
• Time in Patent Office: 2,910 Days
• Field of Search: 604/8, 604/19, 604/21, 604/27, 604/28, 604/43, 604/44, 604/46, 604/48, 604/500, 604/93.01, 604/264, 604/265, 604/272, 604/541, 604/540, 604/521, 604/290, 604/523, 606/166, 606/108, 606/167
• US Class Current: 604/8
• CPC Class Codes: A61F 2009/00891 Glaucoma
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00745 using mechanical vibrations, e.g. ultrasonic
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61M 2210/0612 Eyes
• CPC Class Codes: A61M 27/002 Implant devices for drainage of body fluids from one part of the body to another intraocular A61F9/00781; middle ear A61F11/202
• CPC Class Codes: A61M 5/14 Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor

Abstract

Methods of treating ocular disorders are disclosed, such as a method that includes inserting an implant in eye tissue, using a delivery instrument, such that an inlet portion of the implant is in an anterior chamber of an eye and an outlet portion of the implant is in a physiological outflow pathway; removing the delivery instrument from the eye without removing the implant; and conducting fluid comprising a therapeutic substance through the implant and into the physiological outflow pathway. Another method includes inserting an instrument into a physiologic outflow pathway through which aqueous humor drains from an anterior chamber of an eye; separating first and second walls of tissues which comprise the physiologic outflow pathway by injecting a fluid comprising a drug from the instrument while the instrument remains in the physiologic outflow pathway; and withdrawing the instrument following the injection with said fluid remaining within the eye such that the drug has a therapeutic effect on the eye.

Claims

1. A method of treating an ocular disorder, comprising:

using a delivery instrument to insert an implant in eye tissue such that an inlet portion of the implant is in an anterior chamber of an eye and an outlet portion of the implant is in a physiologic outflow pathway so as to conduct aqueous humor from the anterior chamber to the physiologic outflow pathway through the implant;

removing the delivery instrument from the eye without removing the implant; and

providing a fluid comprising a therapeutic substance into the anterior chamber so as to conduct the fluid comprising the therapeutic substance through the implant and into the physiologic outflow pathway such that the therapeutic substance has a pharmacological effect on the eye.

2. The method of claim 1, wherein conducting fluid comprises infusing the therapeutic substance into the inlet portion of the implant.

3. The method of claim 1, wherein conducting fluid comprises conducting the fluid comprising the therapeutic substance from the inlet portion of the implant to the outlet portion of the implant.

4. The method of claim 1, wherein the fluid travels through the anterior chamber of the eye to the implant.

5. The method of claim 4, wherein the fluid travels through a delivery lumen to the implant.

6. The method of claim 5, wherein the delivery lumen is in fluid communication with a lumen of the implant.

7. The method of claim 6, wherein the delivery lumen is coupled to the lumen of the implant.

8. The method of claim 1, wherein the physiologic outflow pathway comprises an aqueous pathway.

9. The method of claim 8, wherein the physiologic outflow pathway comprises Schlemm'"'"'s canal.

10. The method of claim 9, wherein the eye tissue comprises trabecular meshwork.

11. The method of claim 1, wherein the therapeutic substance is selected from the group consisting of a pharmaceutical, a gene, a growth factor, and an enzyme.

12. The method of claim 1, wherein the therapeutic substance is selected from the group consisting of an antiglaucoma drug, a beta-adrenergic antagonist, a TGF-beta compound, and an antibiotic.

13. The method of claim 1, wherein conducting aqueous humor from the anterior chamber to the physiologic outflow pathway through the implant and conducting fluid comprising a therapeutic substance through the implant and into the physiologic outflow pathway are performed simultaneously.

14. A method of treating an ocular disorder, comprising:

inserting an implant through an incision in an eye;

positioning the implant in the eye such that an inlet portion of the implant is in an anterior chamber of the eye and an outlet portion of the implant is in a physiologic outflow pathway with the inlet and outlet portions being in fluid communication so as to conduct aqueous humor from the anterior chamber to the physiologic outflow pathway through the implant;

providing a delivery lumen such that the delivery lumen is in fluid communication with the implant; and

infusing a fluid external to the eye through the delivery lumen into the anterior chamber such that the fluid flows from the inlet portion of the implant to the outlet portion of the implant and into the physiologic outflow pathway so that the fluid has a pharmacological effect on the eye.

15. The method of claim 14, wherein the method further comprises using a delivery instrument to transport the implant.

16. The method of claim 15, wherein the implant is transported through eye tissue.

17. The method of claim 15, wherein the implant is transported through the anterior chamber of the eye.

18. The method of claim 14, wherein providing a delivery lumen comprises coupling the delivery lumen to the inlet portion of the implant.

19. The method of claim 14, wherein providing a delivery lumen comprises coupling the delivery lumen to a lumen of the implant such that the lumens are in fluid communication.

20. The method of claim 14, wherein the fluid comprises a drug.

21. The method of claim 14, wherein the fluid comprises a therapeutic agent.

22. The method of claim 14, wherein the fluid comprises a therapeutic substance selected from the group consisting of a pharmaceutical, a gene, a growth factor, and an enzyme.

23. The method of claim 14, wherein the fluid comprises a therapeutic substance selected from the group consisting of an antiglaucoma drug, a beta-adrenergic antagonist, a TGF-beta compound, and an antibiotic.

24. The method of claim 14, wherein the physiologic outflow pathway comprises an aqueous pathway.

25. The method of claim 24, wherein the physiologic outflow pathway comprises Schlemm'"'"'s canal.

26. A method of treating an ocular disorder, comprising:

inserting an instrument into an anterior chamber of an eye;

advancing the instrument through eye tissue separating the anterior chamber from a physiologic outflow pathway through which aqueous humor drains from the anterior chamber and inserting the instrument into the physiologic outflow pathway;

separating first and second walls of tissues which comprise the physiologic outflow pathway by injecting a fluid comprising a drug from the instrument while the instrument remains in the physiologic outflow pathway;

disposing an implant between the first and second walls of tissues with at least a portion of the implant extending into and through a section of the physiologic outflow pathway; and

withdrawing the instrument following the placement of the implant in the eye and with said fluid remaining within the eye such that the drug has a pharmacological effect on the eye.

27. The method of claim 26 additionally comprising contacting scleral tissue with the instrument before separation.

28. The method of claim 26, wherein at least one of the separated tissues is scleral tissue.

29. The method of claim 28, wherein the fluid comprises a therapeutic substance selected from the group consisting of a pharmaceutical, a gene, a growth factor, and an enzyme.

30. The method of claim 28, wherein the fluid comprises a therapeutic substance selected from the group consisting of an antiglaucoma drug, a beta-adrenergic antagonist, a TGF-beta compound, and an antibiotic.

31. The method of claim 26, wherein disposing the implant involves disposing the implant such that a distal end of the implant extends through the section of the physiologic outflow pathway and contacts the second wall.